Abstract

The present invention relates to a composition for detecting nucleic acids by using a Cas12j protein and an exponential amplification reaction (EXPAR), and a use thereof. A nucleic acid system according to the present invention can stably detect various target nucleic acids, and has excellent detection ability and analysis ability for actual clinical samples, and thus can be applied to diagnostic platforms for various diseases.

IPC Classes  ?

• C12Q 1/6816 - Hybridisation assays characterised by the detection means
• C12Q 1/6844 - Nucleic acid amplification reactions
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/22 - Ribonucleases

Abstract

The present application relates to an antiviral pharmaceutical composition comprising an estrogen-related receptor γ (ERRγ) inhibitor as an active ingredient. The antiviral pharmaceutical composition comprising an ERRγ inhibitor as an active ingredient, according to embodiments of the present application, has an antiviral effect, and in particular, can exhibit the effect of preventing or treating RNA viral infection. Specifically, the ERRγ inhibitor, particularly an ERRγ inverse agonist, inhibits ERRγ activity in cells infected with RNA virus, thereby blocking SREBP1c-mediated fatty acid biosynthesis, and thus can exhibit broad-spectrum antiviral efficacy.

IPC Classes  ?

• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a novel oxadiazole derivative and a composition for preventing or treating cancer, comprising same. The oxadiazole derivative compound according to the present invention has the activity of inhibiting MDH1 and MDH2 enzymes, exhibits proliferation inhibitory and tumor inhibitory activities against cancer cells and effective proliferation inhibitory efficacy against KRAS-LKB1 co-mutation cancer cells, and exhibits an excellent anticancer effect when co-administered with an anticancer agent such as an anti-PD-1 inhibitor or gefitinib. Therefore, the oxadiazole derivative compound according to the present invention is expected to be effectively used as a therapeutic agent for various cancers.

IPC Classes  ?

• C07D 271/113 - 1,3,4-OxadiazolesHydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
• A61K 31/4245 - Oxadiazoles
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

The present invention relates to a novel oxazole derivative and a composition for preventing or treating cancer, comprising same. The oxazole derivative compound according to the present invention has MDH1 and MDH2 enzyme inhibitory activities, exhibits proliferation inhibitory and tumor inhibitory activities against cancer cells, exhibits an effective proliferation inhibitory effect on KRAS-LKB1 co-mutation cancer cells, and exhibits a better anticancer effect when co-administered with an anticancer agent such as an anti-PD-1 inhibitor or gefitinib. Therefore, the oxazole derivative compound according to the present invention is expected to be effectively used as a therapeutic agent for various cancers.

IPC Classes  ?

• C07D 263/58 - BenzoxazolesHydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• A61K 31/423 - Oxazoles condensed with carbocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

The present invention relates to a method for preparing organ-specific mesenchymal cells from pluripotent stem cell-derived intestinal organoid stromal cells. By using cells derived from stromal cell layers adjacent to intestinal organoids for differentiation into organ-specific mesenchymal cells, the present invention can greatly increase the efficiency of differentiation into stromal cells through the regulation of retinoic acid (RA) and hedgehog (HH) signaling pathways, and can increase the expression of organ-specific markers without exhibiting undifferentiated state cell characteristics, and thus mesenchymal cells having well-simulated biological characteristics can be prepared.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of inflammatory diseases or autoimmune diseases, containing a pyridine compound as an active ingredient. The pyridine compound of the present invention used as the active ingredient of the pharmaceutical composition can significantly inhibit innate immune responses and inflammatory responses by inhibiting the activity of IRAK4 with very high efficacy, and thus can be effectively used for the prevention or treatment of inflammatory diseases or autoimmune diseases.

IPC Classes  ?

• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61P 37/00 - Drugs for immunological or allergic disorders
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

The present invention relates to a technique for diagnosing and monitoring neurodegenerative diseases on the basis of body fluid analysis. If a detection system of the present invention is used, effective real-time diagnostic efficiency can be exhibited while a problem such as noise is minimized. Particularly, since miRNAs present in trace amounts are detected in a high detection efficiency and are diagnosed, an excellent diagnostic effect on neurodegenerative diseases including Alzheimer's disease is exhibited.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

Bifidobacterium pseudolongum Bifidobacterium pseudolongum Bifidobacterium pseudolongum strain deposited under accession number KCTC 15133BP, a culture of the strain, a lysate of the strain, an extract of the strain, or a mixture thereof, according to the present invention, alleviates inflammatory cell infiltration and fibrosis in the liver, and exhibits the effects of inhibiting cholesterol synthesis and inhibiting triglyceride accumulation in the liver, and thus can be used for treating fatty liver diseases, particularly nonalcoholic fatty liver disease.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A61K 35/745 - Bifidobacteria
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23K 10/16 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions

Abstract

The present invention relates to a transformant having isoprene-producing ability The transformant of the present invention has superior isoprene-producing ability by introduction, into methanotrophic bacteria, a nucleotide sequence encoding exogenous isoprene synthase, a nucleotide sequence encoding exogenous isopentenyl diphosphate isomerase, and a nucleotide sequence encoding exogenous 4-hydroxy-3-methylbut-2-enyl diphosphate reductase, and thus can be effectively used for isoprene biosynthesis.

IPC Classes  ?

• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
• C12P 5/00 - Preparation of hydrocarbons

Abstract

The present invention relates to a novel enzyme capable of producing multi-hydroxy derivatives from polyunsaturated fatty acids and a method for producing multi-hydroxy derivatives of polyunsaturated fatty acids using the same.

IPC Classes  ?

• C12P 7/6427 - Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
• A61P 35/00 - Antineoplastic agents
• C11C 3/00 - Fats, oils or fatty acids obtained by chemical modification of fats, oils or fatty acids, e.g. by ozonolysis
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12P 7/6432 - Eicosapentaenoic acids [EPA]
• C12P 7/6434 - Docosahexenoic acids [DHA]
• C12P 17/02 - Oxygen as only ring hetero atoms

Abstract

The present disclosure relates to a method for two-dimensionally culturing an intestinal stem cell population in a chemically defined medium and a use thereof, and also relates to a method for differentiating the intestinal stem cell population into 2.5-dimensional intestinal epithelial cells and a use thereof.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention relates to a medium composition for herbicidin production comprising one or more amino acids among isoleucine, glutamine, proline, and leucine; a composition for herbicidin production; a method for producing herbicidin, the method comprising a step of culturing a Streptomyces scopuliridis strain in a medium containing one or more amino acids among isoleucine, glutamine, proline, and leucine; a method for increasing herbicidin production; or a use of the composition for herbicidin production.

IPC Classes  ?

• C12N 1/38 - Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factorsStimulation of growth by removal of a chemical compound
• C12N 1/20 - BacteriaCulture media therefor
• C12P 19/40 - Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
• C12R 1/465 - Streptomyces

Abstract

The present invention relates to a composition for promoting hair growth or preventing or treating hair loss, the composition comprising a microorganism of the genus Janthinobacterium or violacein. The microorganism of the genus Janthinobacterium or violacein according to one aspect or a solvate or salt thereof has the effects of increasing the sphere size of dermal papilla cells, inducing hair follicle growth, inducing the differentiation or proliferation of hair follicle stem cells, and reducing hair follicle degeneration, and thus has the effect of promoting hair growth or treating hair loss.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• A61Q 7/00 - Preparations for affecting hair growth

Abstract

The present invention relates to a lipid for enhancing the immunogenicity of mRNA/LNP vaccines and, more specifically, to a lipid nanoparticle comprising a lipid that includes propionate, butyrate, or both, and a drug delivery carrier utilizing same. The lipid nanoparticle according to the present invention can significantly enhance the immunogenicity of a nucleic acid-based vaccine contained therein.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Abstract

The present invention relates to a composition for preventing, treating, or alleviating obesity or liver diseases, comprising a thioredoxin-interacting protein (TXNIP)-derived peptide as an active ingredient. The TXNIP-derived peptide according to the present invention inhibits adipogenesis, exhibits an anti-obesity effect, and exhibits the effects of inhibiting metabolic dysfunction-associated fatty liver development and liver fibrosis, and thus can be used for the prevention or treatment of obesity or liver diseases.

IPC Classes  ?

• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to a pharmaceutical composition for prevention or treatment of fibrosis, comprising directly reprogrammed natural killer (drNK) cells prepared through the reprogramming of isolated cells, and a cell therapy product, and specifically relates to: a pharmaceutical composition for prevention or treatment of fibrotic disease, comprising drNK cells expressing any one or more selected from the group consisting of CD56superbright, CD16superbright, and a combination thereof; and a cell therapy product.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention relates to a pharmaceutical composition and a cellular therapeutic agent for the prevention or treatment of a neurological disease, comprising as active ingredients: a Schwann cell precursor (SCP) prepared from a pluripotent stem cell (PSC) or a somatic cell, or a Schwann cell (SC) differentiated therefrom; and natural killer (NK) cells. Specifically, the SCP expresses any one or more selected from the group consisting of GAP43, SOX10, IGFBP2, and a combination thereof, the SC expresses any one or more selected from the group consisting of S100B, SOX10, and a combination thereof, and the NK cells express any one or more selected from the group consisting of CD56+, CD16+, and a combination thereof.

IPC Classes  ?

• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 25/00 - Drugs for disorders of the nervous system
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/079 - Neural cells
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention relates to an mRNA structure comprising: a gene encoding a target protein or peptide; and a 5' untranslated region (5'-UTR) comprising any one nucleotide sequence selected from the group consisting of SEQ ID NOS: 1 to 15 and linked upstream of the gene encoding the target protein or peptide, or a 3' untranslated region (3'-UTR) comprising any one nucleotide sequence selected from the group consisting of SEQ ID NOS: 16 to 35 and linked downstream of the gene encoding the target protein or peptide. The mRNA structure according to the present invention exhibits high mRNA stability and high expression efficiency of the target protein or peptide, and enables stable expression of the target protein within cells for an extended period of time, even when various target proteins, host cells, or delivery methods are used. Accordingly, the mRNA structure with enhanced protein translation efficiency according to the present invention can be advantageously utilized in various application fields related to target protein expression, such as therapeutic and vaccine development.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/67 - General methods for enhancing the expression
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present disclosure relates to a method of treating cancer using a tryptophanyl-tRNA synthetase (WRS) inhibitor. The WRS is secreted by cancer cells and induces or promotes differentiation of myeloid-derived suppressor cells (MDSCs), which may inhibit anticancer immunity of immune cells, and therefore, the WRS inhibitor may effectively inhibit proliferation of cancer cells by inhibiting expression or activity of the WRS and inhibiting differentiation of MDSCs. Accordingly, the present disclosure may be used as an effective method of ameliorating or treating cancer and a method of enhancing or promoting anticancer efficacy of an anticancer drug, and further, may be usefully utilized as a method of screening a substance that inhibits the expression or activity of WRS as an anticancer drug.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a pharmaceutical composition comprising 4'-thio-5-aza-2'-deoxycytidine or a pharmaceutically acceptable salt thereof for preventing or treating liver diseases. The 4'-thio-5-aza-2'-deoxycytidine of the present invention exhibits excellent effects with respect to treatment and alleviation of liver diseases, particularly nonalcoholic fatty liver diseases and metabolic dysfunction steatohepatitis, and thus can be effectively used for alleviation and treatment of liver diseases.

IPC Classes  ?

• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 35/00 - Antineoplastic agents
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates

Abstract

The present invention provides Dunaliella salina microalgae having the ability to produce beta-carotene at a NaCl concentration of 0.1M or less. In addition, the present invention provides a method for producing beta-carotene, comprising a step of culturing the Dunaliella salina microalgae.

IPC Classes  ?

• C12N 1/12 - Unicellular algaeCulture media therefor
• C12P 23/00 - Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes
• C12R 1/89 - Algae

Abstract

A method according to the present disclosure improves sleep states, maintains a sound sleep, restores the balance of gut microbiota disrupted by sleep disorders, and supports the management of health including metabolic syndrome. Under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, the Limosilactobacillus reuteri LM1063 strain was deposited with the international depositary authority: the Korean Collection for Type Cultures on Mar. 23, 2017, under the Accession Number: KCTC 13232BP.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention relates to: an RNA structure for improving the efficiency of non-naturally occurring protein translation, the structure comprising a nucleic acid sequence that comprises two or more stem structures and two or more loop structures, the nucleic acid sequence being a virus-derived internal ribosome entry site (IRES); and a translation-triggering RNA (ttRNA), which is an mRNA structure comprising same. The RNA structure according to the present invention has high RNA stability and protein expression efficiency, low immunogenicity, and can stably express a target protein in a cell for a long time even if various target proteins, various introduction cells and introduction methods are used. Therefore, the mRNA structure comprising the RNA structure having improved protein translation efficiency of the present invention can be effectively utilized in various application fields related to target protein expression, such as the development of therapeutic agents and vaccines.

IPC Classes  ?

• C12N 15/67 - General methods for enhancing the expression
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a novel lipid compound for tissue-specific delivery and a lipid nanoparticle (LNP) including same. The lipid nanoparticle includes, as a component, a lipid compound modified such that an active substance therein is selectively delivered into cells of a specific tissue such as lymph nodes, the spleen, the retina, cancer, the brain, the liver, and the like in vivo, thereby preventing side effects and safely exhibiting a desired level of effects. These tissue-specific, non-viral LNP carriers can be effectively utilized for the prevention of infectious diseases and the treatment of rare and intractable (hereditary) diseases (macular degeneration, diabetic retinopathy, hereditary retinal degeneration, cancer, brain diseases, liver diseases, and etc.), where targeted and selective delivery within the body is crucial.

IPC Classes  ?

• C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical
• C07H 15/12 - Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of a saccharide radical
• A61K 9/51 - Nanocapsules
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 27/02 - Ophthalmic agents
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to a plastic-degrading enzyme derived from Galleria mellonella, and use thereof, the enzyme exhibiting an activity of oxidizing or degrading plastics such as polyethylene (PE), and thus can remove a large amount of consumed plastics or leftover plastics in an eco-friendly manner.

IPC Classes  ?

• B09B 3/60 - Biochemical treatment, e.g. by using enzymes
• B29B 17/04 - Disintegrating plastics
• A23K 20/10 - Organic substances
• A23K 50/90 - Feeding-stuffs specially adapted for particular animals for insects, e.g. bees or silkworms
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• B09B 101/75 - Plastic waste

Abstract

AkkermansiaBacteroidesAlistipesEscherichia coliEscherichia coli (E. coli).

IPC Classes  ?

• A61K 38/53 - Ligases (6)
• A61P 35/00 - Antineoplastic agents
• A23L 33/195 - Proteins from microorganisms
• A61K 35/741 - Probiotics

Abstract

The present invention relates to a composition for improving skin, comprising an extract of Lavandula angustifolia stem-derived callus or a fraction thereof as an active ingredient and a method for preparing same, the method comprising the steps of: (a) inducing callus from Lavandula angustifolia stem tissue; (b) culturing the Lavandula angustifolia stem-derived callus induced in step (a) in the presence of methyl jasmonate; and (c) obtaining an extract of the Lavandula angustifolia stem-derived callus cultured in step (b).

IPC Classes  ?

• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61K 8/35 - Ketones, e.g. quinones, benzophenone
• A61Q 19/00 - Preparations for care of the skin
• A61Q 19/08 - Anti-ageing preparations
• A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

The present invention relates to a dual structure-switching aptamer-mediated signal amplification cascade system for virus detection. The system, according to the present invention, has the advantages of having a simple virus detection procedure and enabling specific detection even within a short detection time of 30 minutes or less, thereby not requiring expensive enzymes and thermal control equipment. In addition, the system has the advantage of enabling the detection of an actual pathogen (especially a virus) at a level of 1.0 PFU.

IPC Classes  ?

• C12Q 1/682 - Signal amplification
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

3124511010) group.

IPC Classes  ?

• A01N 31/08 - Oxygen or sulfur directly attached to an aromatic ring system
• A01N 31/16 - Oxygen or sulfur directly attached to an aromatic ring system with two or more oxygen or sulfur atoms directly attached to the same aromatic ring system
• A01P 3/00 - Fungicides
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A61K 31/05 - Phenols
• A61P 31/04 - Antibacterial agents

Abstract

The present invention relates to a nanocomposite for cancer diagnosis and treatment, a composition comprising same for cancer treatment, and an ultrasonic contrast agent for cancer diagnosis and, more specifically, to a nanocomposite comprising at least one coordination nanoparticle for cancer diagnosis and treatment, a composition comprising same for cancer treatment, and a contrast agent for cancer diagnosis, wherein the coordination nanoparticle includes: a perfluorocarbon coordinating iron ions; at least one dopamine compound selected from the group consisting of dopamine and dopamine analogs; and a nucleophile.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 49/22 - Echographic preparationsUltrasound imaging preparations
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates to novel cinnamamide derivatives and use thereof in preventing or treating cancer.

IPC Classes  ?

• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07C 235/80 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
• C07D 213/30 - Oxygen atoms

Abstract

The present invention relates to: a nucleic acid delivery complex comprising lipid nanoparticles; a composition comprising the nucleic acid delivery complex for delivering nucleic acids; and a nucleic acid delivery method comprising a step of treating, with the nucleic acid delivery complex, an object to which a nucleic acid is delivered.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 9/51 - Nanocapsules
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

The present invention relates to a technology for detecting a target nucleic acid by using an argonaute protein and an artificial nucleic acid circuit. The system according to the present invention can specifically detect target pathogens added to a human sample with 100% clinical sensitivity without nucleic acid amplification and separate extraction steps, and can directly identify target pathogens collected from the surface of an object by using the system together with a three-dimensional nanopillar array structure. In addition, since a trigger sequence cleaved by an Ago protein is designed to be used as a guide, a single protein is used, and thus manufacturing is simpler than that of a conventional nucleic acid detection circuit, and cost are reduced in that target pathogens can be detected with high sensitivity even with trace amounts of target nucleic acid sequences as long as the Ago protein, a reporter, and a reporter complement according to the system of the present invention are not depleted. In addition, the system according to the present invention proceeds in a single step, and can be easily applied to the detection of various target nucleic acid sequences by appropriately changing a nucleic acid recognition site to match a target pathogen.

IPC Classes  ?

• C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer

Abstract

The present invention relates to a polymer composite comprising biomass, and a method for producing same, and, more specifically, to: a method for producing a polymer composite comprising Chlorella-derived biomass, the method comprising a saccharification step of performing acid-catalyzed saccharification on Chlorella biomass in the presence of an acid, a step of mixing the saccharification solution, obtained in the saccharification step, and calcium hydroxide so as to neutralize same, a step of recovering, from the neutralization product obtained in the neutralization step, a solid part containing a precipitated salt, and a step of mixing the solid part and a polymer so as to prepare a polymer mixture; and the polymer composite composite, which comprises: the solid part of a neutralized saccharification solution obtained after acid-catalyzed saccharification of Chlorella biomass and neutralization; and a polymer.

IPC Classes  ?

• C08K 5/1545 - Six-membered rings
• C08L 23/08 - Copolymers of ethene
• C08L 67/02 - Polyesters derived from dicarboxylic acids and dihydroxy compounds
• C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones

Abstract

The present invention relates to a novel histidine amide cholesterol compound and RNA delivery lipid nanoparticles comprising same. The present invention can have improved mRNA delivery efficiency and expression efficiency while having biocompatibility.

IPC Classes  ?

• C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
• A61K 9/51 - Nanocapsules
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a method for improving muscle strength, and/or muscle mass by administering a composition containing as an active ingredient at least one selected from the group consisting of Akkermansia muciniphila cells, a culture thereof and a lysate thereof, and a method for preventing or treating muscle diseases where muscle strength and/or mass is weakened by sarcopenia, cachexia or muscle wasting.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention relates to a novel benzofuran compound and a pharmaceutical composition comprising same for preventing or treating cancer. The compound according to the present invention or a pharmaceutically acceptable salt thereof binds to hnRNPA2B1 to inhibit the translation of HIF-1α, thus exhibiting an excellent prophylactic and therapeutic effect on cancer diseases of various carcinomas. In particular, the present invention exhibits an effect of having excellent anticancer activity through the effect of inhibiting cancer metastasis as well as the effect of inhibiting cell death.

IPC Classes  ?

• C07D 493/04 - Ortho-condensed systems
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

e.g.e.g., a fluorescent signal). In some aspects, such methods are useful for diagnosing and treating a subject such as a subject having a cancer.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 9/22 - Ribonucleases
• C12Q 1/6823 - Release of bound markers

Abstract

The present invention relates to a novel antibody specifically binding to GPC3 or an antigen-binding fragment thereof, a chimeric antigen receptor comprising an antigen-binding variable fragment of the antibody, and immune cells expressing the chimeric antigen receptor.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to an antibody or an antigen-binding fragment thereof, which specifically binds to TM4SF5 and can thus be effectively used for preventing, treating, and diagnosing diseases caused by the overexpression of TM4SF5.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present disclosure relates to a dual enzyme amplification-based colorimetric sensor system for on-site detection of pathogens. The colorimetric sensor system according to the present disclosure may comprise a combination of the CRISPR/Cas12a system with an enzymatic reaction of urease, thereby facilitating on-site detection of pathogens without separate analytical equipment by analyzing the color change through dual enzyme amplification. In addition, it is possible to selectively change the target by changing the crRNA sequence depending on the target pathogen to be detected, which has the advantage of being applicable to various types of pathogens without limitation. Further, the present disclosure can be used as a point of care service (PoC) system capable of detecting the genes of pathogens directly down to the sub-ng level without separate analysis equipment by applying the detection color value derived using the colorimetric sensor system according to the present disclosure to a smartphone application (app).

IPC Classes  ?

• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C12N 9/22 - Ribonucleases
• C12Q 1/44 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving esterase
• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to a transformed human hepatic stellate cell line, and a use thereof. The hepatic stellate cell line according to the present invention exhibits an improvement in drug response, and when co-cultured with hepatic stellate cells, does not exhibit a functional decrease in the hepatic cells, and thus can be advantageously used in an in vitro culture model.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to an mRNA structure platform capable of expressing a protein with high efficiency.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides

Abstract

The present invention relates to: a transformed strain expressing and secreting Akkermansia muciniphila TARS (AmTARS); and a vector for producing same. More specifically, the present invention relates to an Escherichia coli Nissle 1917 (EcN) strain expressing AmTARS, a composition comprising same, a novel vector for producing same, and an EcN transformation method using same.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a single domain antibody against Serpin A12 and a use thereof. The antibody according to the present invention is a single domain antibody against Serpin A12, which has high affinity for Serpin A12 through high affinity, thereby exhibiting excellent therapeutic efficacy for bone diseases.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61P 19/00 - Drugs for skeletal disorders
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of nontuberculous mycobacteria infection. A CD36 inhibitor, sulfo-N-succinimidyl oleate (SSO), and SSO derivatives, according to an aspect of the present invention, have the effect of inhibiting the growth, proliferation and the like of nontuberculous mycobacteria, and thus can be effectively used in the prevention or treatment of nontuberculous mycobacteria infection or nontuberculous mycobacteria pulmonary disease.

IPC Classes  ?

• C07D 207/28 - 2-Pyrrolidone-5- carboxylic acidsFunctional derivatives thereof, e.g. esters, nitriles
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
• A61P 31/04 - Antibacterial agents
• A61P 11/00 - Drugs for disorders of the respiratory system
• C07D 263/26 - Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

The present invention relates to a fluorescent protein variant for observing cell damage, a gene encoding same, a vector system comprising same and a transgenic cell using same, and uses thereof. It is possible to monitor cell damage in real time of the transgenic cell as the fluorescence expression level that changes depending on the activity of caspase 3 or caspase 7 can be confirmed in real time. Furthermore, the transgenic cell according to the present invention may be used to evaluate the toxicity of various drugs. Accordingly, the present invention can be effectively used in cell damage research or drug development.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention relates to: a microalgae strain with restricted pigment biosynthesis; a method for producing useful substances from same; and a composition comprising the useful substances. The present invention relates to: a microalgae strain with restricted pigment production; a method for producing useful substances derived from the microalgae strain, comprising the steps of culturing the microalgae strain to obtain a culture which is biomass, a culture medium, or a mixture thereof, and obtaining useful substances by separating the useful substances from residues through extraction from the obtained culture, wherein the extracted extract has a white or transparent color; a cosmetic composition containing, in an oil phase part, an oil component extracted from a culture which is biomass of the microalgae strain of the present invention, a culture medium, or a mixture thereof; an artificial meat containing amino acid, protein, or a mixture thereof; and a biodegradable plastic material containing a degreased residue remaining after extracting lipids from the culture which is biomass, a culture medium, or a mixture thereof, or dried biomass of the strain.

IPC Classes  ?

• C12N 1/12 - Unicellular algaeCulture media therefor
• A61K 8/9722 - Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
• A23L 29/00 - Foods or foodstuffs containing additivesPreparation or treatment thereof
• C12P 1/00 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes
• C12R 1/89 - Algae

Abstract

The present invention relates to a promoter for gene expression in retinal cells, and a vector system comprising same. The promoter for gene expression in retinal cells and the vector system including same according to the present invention have a minimal unit for promoter activity and, unlike existing known promoters in retinal cells, maintain a high level of expression of a target gene, and thus can be used to maximize the expression of the target protein in retinal cells.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C12N 5/0793 - Neurons

Abstract

The present disclosure relates to a cell-penetrating peptide, an anticancer peptide, and a pharmaceutical composition for preventing or treating cancer including the same. The cell-penetrating peptide of the present disclosure can further improve a cancer cell growth inhibitory effect of anticancer peptides, especially cancer therapeutic peptides with improved anticancer activity by cyclic structures, and thus can be effectively applied to the prevention or treatment of various cancers.

IPC Classes  ?

• C07K 7/64 - Cyclic peptides containing only normal peptide links
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

The present invention relates to: a novel chimeric antigen receptor containing, as an intracellular signaling domain, an intracellular domain of a receptor containing a dead region; and immune cells expressing the chimeric antigen receptor. In environments in which normal cells are present, the immune cells expressing the chimeric antigen receptor according to the present invention exhibit little or no cytotoxicity and cell death of the immune cells is exhibited, thus ensuring the stability of the normal cells. Conversely, in environments in which target cells are present, the immune cells exhibit more potent cytotoxicity than with conventional techniques utilizing a lone chimeric antigen receptor.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 14/73 - CD4
• C07K 14/735 - Fc receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention relates to two types of novel Bifidobacterium animalis subspecies lactis strains, a Lactobacillus paracasei strain, a Lactobacillus gasseri strain, or a combination thereof and uses thereof. The strains increase mitochondrial synthesis by increasing the activity of AMP-activated protein kinase (AMPK) protein present in muscle cells, thereby improving the ability of muscles to perform exercise, and thus can be used for the improvement of muscle function or can be effectively used as a medicine, a health functional food, or a food, for the prevention, amelioration or treatment of muscle diseases.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• C12R 1/01 - Bacteria or actinomycetales
• C12R 1/225 - Lactobacillus

Abstract

The present invention relates to a novel enzyme capable of producing multi-hydroxy derivatives from polyunsaturated fatty acids and a method for producing multi-hydroxy derivatives of polyunsaturated fatty acids using the same.

IPC Classes  ?

• C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
• A61P 35/00 - Antineoplastic agents
• C11C 3/00 - Fats, oils or fatty acids obtained by chemical modification of fats, oils or fatty acids, e.g. by ozonolysis
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12P 7/6427 - Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
• C12P 7/6432 - Eicosapentaenoic acids [EPA]
• C12P 7/6434 - Docosahexenoic acids [DHA]
• C12P 17/02 - Oxygen as only ring hetero atoms

Abstract

The present invention relates to a cell culture substrate and a method for culturing stem cells using same, wherein the cell culture substrate has a polymer thin film deposited thereon for stem cell cultivation, which can replace animal-derived materials that are essential in pluripotent stem cell culture. According to the present invention, human pluripotent stem cells, which are conventionally cultured using animal-derived feeder cells or Matrigel, can also be cultured on a cell culture vessel that is coated with a polymer thin film and excludes animal-derived materials, whereby safer stem cell therapeutics can be produced.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/074 - Adult stem cells

Abstract

The present invention relates to a method for preparing directly reprogrammed natural killer (drNK) cells or CAR (chimeric antigen receptor) gene introduced CAR-drNK cells using substances and methods that inhibit BCL11B (B-cell leukemia 11B) gene expression and/or function. The present invention also relates to drNK cells or CAR-drNK cells prepared by a BCL11B gene-based cell reprogramming method, and a cell therapeutic and/or a composition for the prevention or treatment of cancer diseases and infectious diseases caused by viruses, bacteria, fungi, and the like, and/or inflammatory diseases, which contain the cells.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

A composition according to the present invention not only improves sleep or maintains sound sleep but also restores the balance of intestinal microorganisms disrupted by sleep disorders, and thus can help in managing health conditions such as metabolic syndrome.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61P 25/20 - HypnoticsSedatives
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

Abstract

The present invention relates to a novel Bifidobacterium longum ssp. infantis strain and use thereof.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/745 - Bifidobacteria
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• C12R 1/01 - Bacteria or actinomycetales

Abstract

The present invention relates to a novel Lactobacillus sp. strain and a use thereof.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/225 - Lactobacillus

Abstract

The present invention relates to a therapeutic agent of a lipase inhibitor for a wide spectrum of RNA viral infections in humans and animals. More specifically, the lipase inhibitor can be used as a therapeutic agent for influenza A virus infection, bovine coronavirus infection, porcine epidemic diarrhea coronavirus infection, bovine rotavirus infection, porcine reproductive and respiratory syndrome virus infection, and sapoviral infection and furthermore, can be utilized as a therapeutic agent for various RNA viral infections in humans and animals, such as infections with SARS COV-1, MERS-COV, Zika virus, dengue fever virus, and hepatitis A and C viruses.

IPC Classes  ?

• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The present invention relates to a composition containing extracts from Garcinia cambogia and Acanthopanax for prevention or treatment of liver diseases and, more specifically, to a composition for prevention or treatment of liver disease, the composition containing, as active ingredients, (i) a Garcinia cambogia extract, hydroxycitric acid (HCA), or a derivative of hydroxycitric acid; and (ii) an Acanthopanax extract, Chiisanogenin, or a derivative of Chiisanogenin.

IPC Classes  ?

• A61K 36/254 - Acanthopanax or Eleutherococcus
• A61K 31/191 - Acyclic acids having two or more hydroxy groups, e.g. gluconic acid
• A61K 31/365 - Lactones
• A61K 36/38 - Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to an indole compound derivative that decomposes IKZF2 and a use thereof. More specifically, a compound of chemical formula 1 provides an agent having a novel mechanism of action against the IKZF2 protein, and thus is useful for the treatment of diseases and disorders related to the IKZF2 protein, and can in particular be effectively used for preventing or treating cancer.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 35/00 - Antineoplastic agents
• C07D 471/04 - Ortho-condensed systems

Abstract

The present invention relates to novel strains having anti-Helicobacter pylori activity and uses thereof.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A01N 63/20 - BacteriaSubstances produced thereby or obtained therefrom
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A61K 35/74 - Bacteria
• A61P 31/04 - Antibacterial agents
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• C12R 1/25 - Lactobacillus plantarum
• C12R 1/225 - Lactobacillus
• C12R 1/01 - Bacteria or actinomycetales

Abstract

The present invention relates to a pharmaceutical composition, health functional food composition or health functional food for the prevention, treatment or amelioration of sarcopenia, comprising at least one of one or more short-chain or medium-chain fatty acids, ester(s) thereof, or triglyceride form(s) thereof. Also, the present invention relates to a composition for the diagnosis of a possible sarcopenia group or a sarcopenia group, the composition comprising, as an active ingredient, an agent for measuring the content of one or more short-chain or medium-chain fatty acids in the blood, and relates to a method for providing information for determining a possible sarcopenia group or a sarcopenia group, the method comprising a step of measuring the content of one or more short-chain or medium-chain fatty acids from the blood of a subject.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A23L 33/12 - Fatty acids or derivatives thereof
• G01N 30/72 - Mass spectrometers
• G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups

Abstract

The present invention relates to a novel compound isolated from spinach, and a composition comprising same for preventing or treating inflammatory diseases, and, more particularly, to a novel medicagenic acid glycoside compound isolated from spinach, a preparation method therefor, and a composition comprising same for preventing or treating inflammatory diseases.

IPC Classes  ?

• C07H 15/256 - Polyterpene radicals
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 36/21 - Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
• A61P 11/06 - Antiasthmatics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07H 1/08 - SeparationPurification from natural products

Abstract

The present invention relates to: a method for converting non-pluripotent cells into pluripotent cells; cells produced by the method; and uses thereof. The pluripotent cells of the present invention have low tumorigenicity while having excellent cell differentiation ability and pluripotency capable of differentiating into three germ layers, and can specifically separate pluripotent cells in the intermediate stage of reprogramming, and thus, it is possible to produce pluripotent cells having characteristics different from conventional induced pluripotent stem cells.

IPC Classes  ?

• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• C12N 5/074 - Adult stem cells

Abstract

The present invention relates to stem cells with suppressed FTO gene expression, immune cells differentiated therefrom, and uses thereof. In the present invention, it was found that suppressing the expression of the FTO gene in immune cells significantly improves cytolytic activity and that the immune cells differentiated from the stem cells with FTO gene expression suppressed therein exhibited superior cytolytic activity against cancer cells, whereby the limitations of existing immune cell therapies, such as immune mismatch and limited cell numbers, were overcome. Furthermore, in the present invention, the CAR gene was introduced into the location of the FTO gene in stem cells to generate stem cells that delete the FTO gene while expressing the CAR gene. The immune cells differentiated from the stem cells demonstrated significantly superior cytolytic activity against cancer cells. Therefore, the present invention can be effectively utilized as an immune anticancer cell therapy.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a complex for bioimaging, diagnosis, and treatment of cancer cells. The complex of the present invention comprises fluorescent nanoparticles and a manganese salt conjugated to the surface of the fluorescent nanoparticles, and the fluorescence of the fluorescent nanoparticles in the complex is quenched due to the conjugation of the manganese salt.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61P 35/00 - Antineoplastic agents
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals

Abstract

Provided is a composition for the prevention or treatment of Hutchinson-Gilford Progeria syndrome (HGPS) using gene editing, which contains sgRNA that hybridizes to mRNA encoding progerin, which causes HGPS, and a gene encoding Cas13 protein acting on the same. When introduced into the cell of a subject to be treated and only the mRNA encoding progerin is selectively cut. There is no need for co-prescribing with other therapies and fewer side effects occur than traditional farnesyltransferase inhibitors (FTIs). The efficiency is higher than when treated using homologous recombination (HR) at the DNA level, treatment using composition can be made reversibly, and the composition can be applied specifically compared to targeted treatment using RNAi (RNA interference), and has fewer side effects. Compared to treatment using CRISPR/Cas9, which directly acts on DNA and produces irreversible results, treatment using composition is reversible and selectively cut only mRNA encoding progerin, thereby ensuring safety.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 38/46 - Hydrolases (3)
• A61P 39/00 - General protective or antinoxious agents
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

An NK cell cytotoxicity prediction method of the present invention can predict the cytotoxicity of NK cells with respect to cancer cells according to ligand expression levels by analyzing active or inhibitory ligands that contribute highly to the toxicity of NK cells, thereby also predicting the activity of immune cells used in anticancer cell treatment, in addition to the activity of NK cells in various cancer types, and thus can be effectively used as a tool for patient-specific anticancer treatment. In addition, the CAR-NK cell cytotoxicity prediction method of the present invention can predict the cytotoxicity of CAR-NK cells with respect to cancer cells according to the expression levels of ligands expressed on the surface of cancer cells and target antigens of CAR.

IPC Classes  ?

• G16B 40/20 - Supervised data analysis
• G16B 25/00 - ICT specially adapted for hybridisationICT specially adapted for gene or protein expression
• G16B 45/00 - ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention provides an impedance-based organoid evaluation system comprising an organoid deformation generating unit including a first tube and a plurality of second tubes having a diameter smaller than that of the first tube, connected to one end of the first tube or inserted therein; and an impedance measuring unit connected to the organoid deformation generating unit and including an impedance analyzer for measuring the impedance of the organoid, and evaluating the organoid from the impedance measured by the impedance measuring unit.

IPC Classes  ?

• G01N 27/04 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance
• C12M 1/26 - Inoculator or sampler
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• G01N 33/483 - Physical analysis of biological material

Abstract

The present invention relates to a CD5 antibody and a chimeric antigen receptor (CAR) including the same. The chimeric antigen receptor of the present invention may be expressed in an immune cell to be utilized for an immuno-oncology therapy having reduced toxicity against a normal T cell.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to novel peptides having anti-inflammatory and tissue regenerative actions and uses thereof.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a novel signal sequence peptide and a vector comprising a polynucleotide encoding same. The signal sequence peptide can induce a protein linked thereto to be secreted to the outside of a cell, and thus, when the signal sequence peptide is used or a recombinant microorganism transformed with the vector is used, the signal sequence peptide expresses a target protein and then secretes the target protein to the outside of a cell, thus enabling the target protein to exhibit the activity and function thereof.

IPC Classes  ?

• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

2-62-6 aminoalcohol and a vegetable oil containing neutral fats, which provide at least two types of fatty acids through hydrolysis.

IPC Classes  ?

• C12P 17/06 - Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
• C12P 7/04 - Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
• C12P 13/02 - Amides, e.g. chloramphenicol
• A61K 8/42 - Amides
• A61Q 19/00 - Preparations for care of the skin
• A23K 20/10 - Organic substances
• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61P 35/00 - Antineoplastic agents
• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

The present invention relates to a target for stably forming immunological synapses and improving cytolytic activity in immune cells, and use thereof, and uses an inhibitor of NgR1 protein activity or expression, and thus can improve the stability of synapse formation and can improve cytolytic activity or cytotoxicity, and uses the NgR1 protein as a target so as to measure activity or expression level, and thus can screen for novel anticancer agents. In addition, the present invention can promote the formation of immunological synapses, which are points of contact between immune cells and cancer cells, and can also regulate, in organs and tissue in the body, cell-to-cell contact between various cells that are the same or different from each other, including immune cells, cancer cells, nerve cells and the like, and thus can regulate cell functions.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention provides a compound represented by chemical formula 1, an optical isomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for preventing or treating Wnt/β-catenin signaling-associated diseases, comprising same.

IPC Classes  ?

• C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• C12N 1/20 - BacteriaCulture media therefor
• A61K 38/00 - Medicinal preparations containing peptides
• C12R 1/465 - Streptomyces

Abstract

The present invention relates to a culture method for non-xenogeneic culturing of intestinal stem cells on a culture dish coated with a polymeric thin film, which does not include xenogeneic components such as Matrigel, and a use thereof. The method for culturing intestinal stem cells according to the present invention enables easy and rapid cultivation of homogeneous cells, enables mass-cultivation of cells at a low cost, and eliminates the risk of xenogeneic infection by culturing cells in a non-xenogeneic culture environment, thereby enabling the development of cell therapeutics that can actually be transplanted in practice. Another advantage is that cells can be cultured in a state in which cellular characteristics are maintained even during organ subculture and cryopreservation. Furthermore, the method for producing intestinal epithelial cells, according to the present invention, enables intestinal organoid-derived intestinal stem cells cultured in a non-xenogeneic culture environment to differentiate into intestinal epithelial cells in the same non-xenogeneic culture environment.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

The present invention relates to a composition for preventing or treating cancer, comprising a dual expression vector, and more specifically, to a method for effectively treating cancer by simultaneously inducing the actions of cancer metabolism drugs and cancer immunotherapy drugs by using a dual expression vector for simultaneously expressing an HIF-1α inhibitor and anticancer cytokines.

IPC Classes  ?

• A61K 38/44 - Oxidoreductases (1)
• A61K 38/19 - CytokinesLymphokinesInterferons
• A61K 38/20 - Interleukins
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a novel lipid compound and a lipid nanoparticle (LNP) composition containing same. The lipid compound according to the present invention can either directly or indirectly bind to and surround an active substance through multivalent interactions, thereby increasing the structural stability of the active substance. In addition, when administered in vivo, the lipid nanoparticle composition containing the lipid compound significantly enhances the delivery efficiency into cells and the activity of the active substance, and thus can be useful for the treatment and prevention of diseases.

IPC Classes  ?

• C07C 275/32 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
• C07C 335/08 - Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of a saturated carbon skeleton
• C07D 207/337 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 233/90 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 209/18 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 239/52 - Two oxygen atoms
• C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
• C07D 473/30 - Oxygen atom attached in position 6, e.g. hypoxanthine
• C07D 239/47 - One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
• A61K 9/51 - Nanocapsules

Abstract

One aspect relates to a method which finds an index gene in the same genome as DEG and performs DEG-index-ratio (Dir) transformation using the index gene, so that RNA-seq data can be used to provide information for diagnosis of a disease. The method, according to one aspect, can control individual data variations in RNA-seq results through multidimensional Dir transformation and can be useful in providing information for early diagnosis of a disease.

IPC Classes  ?

• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• G16B 30/10 - Sequence alignmentHomology search
• G16B 50/00 - ICT programming tools or database systems specially adapted for bioinformatics

Abstract

3232322); and a bio-sensor including the MXene transistor.

IPC Classes  ?

• G01N 27/414 - Ion-sensitive or chemical field-effect transistors, i.e. ISFETS or CHEMFETS
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Abstract

The present invention relates to an antimicrobial adjuvant containing a biphenyl derivative compound as an active ingredient, and a technology of various uses thereof. The compound of the present invention reduces the dosage of polymyxin antibiotics, which are administered to inhibit the proliferation of gram-negative bacteria, by enhancing the sensitivity of the gram-negative bacteria with respect to the polymyxin antibiotics, is concomitantly administered with the polymyxin antibiotics to show gram-negative bacteria growth inhibitory and killing effects, may notably reduce side effects such as nephrotoxicity, and may prevent or treat sepsis and septic shock due to antibiotic overuse.

IPC Classes  ?

• A61K 31/06 - Phenols the aromatic ring being substituted by nitro groups
• A61K 38/12 - Cyclic peptides
• A61P 31/04 - Antibacterial agents

Abstract

The present invention relates to a YaxAB nanopore, a system comprising the nanopore and applications thereof. The YaxAB nanopore of the present invention has a funnel-shaped three-dimensional structure so that a change in current blocking according to movement of an analyte captured inside the nanopore can be maximized to enable very sensitive measurements of even the structure of the analyte and minute physical and chemical characteristic changes including dynamic change and the like, and can cause very strong electroosmosis with high cation selectivity such that various types of analytes can be captured and analyzed without limiting the types of overall charges. Additionally, with respect to the nanopore of the present invention, the amino acid sequence of a monomer constituting the nanopore can be adjusted to improve protein purification yield and control oligomerization mechanism, and thus a YaxAB nanopore having a pore size that cannot be formed by a wild-type monomer can be prepared. Furthermore, with respect to the nanopore of the present invention, YaxAB nanopores of various pore sizes can be ensured using one-time purification, and a nanopore of a desired pore size can be selectively ensured. Therefore, limitations of a conventional biological nanopore with a fixed pore size can be overcome such that, with respect to the YaxAB nanopore of the present invention, the size of a nanopore can be adjusted according to the size of an analyte. Additionally, the YaxAB nanopore of the present invention has analyte analysis spectrums of a very wide dynamic range of detection from a small analyte up to a large analyte, resulting from the funnel-shaped three-dimensional structure with a wide inlet and a narrow outlet. Moreover, the YaxAB nanopore of the present invention has the largest nanopore structure among biological nanopores up to now, and large-sized analytes that cannot be detected by conventional biological nanopores can undergo single molecule detection and analysis on the basis of a funnel structure with a large inlet. In addition, the present invention has established an optimized composition of a membrane in which the YaxAB nanopore can exist stably, and, by using a sensor implemented on the basis thereof, various types of analytes having relatively various sizes and charges can be qualitatively and quantitatively analyzed at a single molecular level with very high resolution and sensitivity.

IPC Classes  ?

• G01N 33/487 - Physical analysis of biological material of liquid biological material
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

The present invention relates to a vector that operates in strains of the Bacteroides genus, which are beneficial gut microbes. The vector carries the nucleic acid sequence of SEQ ID NO: 1 necessary for the transformation of Escherichia coli and Bacteroides strains, and the nucleic acid sequence of SEQ ID NO: 2 including the origin of replication for Bacteroides strains. By recombining the nucleic acid sequence of SEQ ID NO: 2 with that of SEQ ID NO: 1, the vector can stably exist and autonomously replicate within Bacteroides strains to maintain a high number of copies. Thus, the vector can be advantageously used as a gut biosensor or for manufacturing tool for microbiome-based therapeutic agents in the future.

IPC Classes  ?

• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli

Abstract

The present invention relates to a localized surface plasmon resonance (LSPR) sensor and a manufacturing method therefor, wherein the LSPR comprises a metal nanostructure layer, a graphene layer formed on the metal nanostructure layer and in contact with the metal nanostructure layer, electrodes formed at both ends of the graphene layer, and a receptor, disposed on the top of the graphene layer, specific for a detection target substance.

IPC Classes  ?

• G01N 21/552 - Attenuated total reflection
• G01N 21/25 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
• G01N 21/59 - Transmissivity
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
• B82Y 40/00 - Manufacture or treatment of nanostructures

Abstract

The present invention relates to mature intestinal organoid-derived mesenchymal stromal cells, and a use thereof. The mature intestinal organoid-derived mesenchymal stromal cells according to the present invention can act directly on a lesion site to significantly enhance regeneration and engraftment efficacy, and thus can significantly enhance the efficiency of transplantation. Further, the mature intestinal organoid-derived mesenchymal stromal cells according to the present invention have excellent efficacy due to being capable of regenerating damaged regions immediately and directly, unlike conventional mesenchymal stem cell therapeutic agents, allow for the application of a simplified subculture method, can maintain the characteristics thereof even when frozen and thawed, and can be utilized in allogeneic transplantation, thus having the advantage of a high likelihood of universal applicability.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

Citri tangerinae SemenCitri tangerinae Semen extract; and use thereof. The Citri tangerinae Semen extract of the present invention inhibits, in vivo, inflammatory responses caused by particulate matter or endotoxin contained in particulate matter, and increased expression of cell adhesion molecules, and thus can be applied to the prevention, amelioration or treatment of diseases caused by particulate matter or endotoxin contained in particulate matter.

IPC Classes  ?

• A61K 36/752 - Citrus, e.g. lime, orange or lemon
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a high-performance mature human intestinal organoid regenerative therapeutic agent derived from pluripotent stem cells. The high-performance mature human intestinal organoid regenerative therapeutic agent derived from pluripotent stem cells according to the present invention includes peristromal cell layers containing mesenchymal stromal cells, derived from the intestine, as the microenvironment around the intestine. That is, the high-performance mature human intestinal organoid regenerative therapeutic agent derived from pluripotent stem cells according to the present invention can exhibit high engraftment ability when transplanted together with peripheral cell layers around intestinal organoids and can exhibit superior regenerative ability through intestinal stem cells present in mature intestinal organoids, and therefore is likely to be useful as a regenerative therapeutic agent.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

The present invention relates to a novel antibody or an antigen-binding fragment thereof, which specifically binds to PD-L1, a chimeric antigen receptor comprising an antigen-binding variable fragment of the antibody, immune cells expressing the chimeric antigen receptor, and a pharmaceutical composition for treating or preventing cancer, the pharmaceutical composition comprising the immune cells.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 14/725 - T-cell receptors
• A61P 35/00 - Antineoplastic agents
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Abstract

The present invention relates to a novel Eutreptiella sp. strain and a method for producing fatty acids by using same and, more specifically, to: an Eutreptiella sp. strain having the ability to produce fatty acids; and a method for producing fatty acids, the method comprising a step of culturing an Eutreptiella sp. strain and a step of extracting fatty acids from the strain.

IPC Classes  ?

• C12N 1/10 - ProtozoaCulture media therefor
• C12P 7/6409 - Fatty acids
• C12R 1/90 - Protozoa

Abstract

The present invention provides: compounds having a specific chemical structure and having the activity of inhibiting or decomposing CDK2 and/or CDK9, or pharmaceutically acceptable salts thereof; and a method for preparing same. The present invention provides a composition comprising the compounds or pharmaceutically acceptable salts thereof. The present invention provides: a use of the compounds, salts thereof, and composition comprising same according to the present invention for inhibiting or decomposing CDK2 and/or CDK9; and medicinal uses for preventing or treating diseases associated with same. The present invention also provides a method for preventing or treating CDK2 and/or CDK9-related diseases, the method comprising administering, to an individual in need of treatment, an effective amount of the compounds, salts thereof, or composition comprising same according to the present invention.

IPC Classes  ?

• C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
• A61K 31/52 - Purines, e.g. adenine
• A61P 35/00 - Antineoplastic agents
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

The present invention relates to a naked eye detection method for SARS-CoV-2 RdRp mutations. In the present invention, a colorimetric detection method using the CRISPR-Cas12a system was developed, allowing for easy diagnosis of SARS-CoV-2 RNA using the naked eye. Notably, the detection method according to the present invention is characterized by the ability to specifically and sensitively identify different mutations of SARS-CoV-2.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/6816 - Hybridisation assays characterised by the detection means
• C12Q 1/6844 - Nucleic acid amplification reactions

Abstract

The present invention relates to: a fluorescent probe compound represented by chemical formula 1 or chemical formula 2; and a composite comprising bioceramics, and a fluorescent probe compound represented by chemical formula 1 and/or a fluorescent probe compound represented by chemical formula 2, which are bound to the bioceramics.

IPC Classes  ?

• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• A61K 49/00 - Preparations for testing in vivo
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention relates to a method for producing a dimeric stilbene using a plant callus culture solution. More specifically, the present invention relates to a method for producing a dimeric stilbene using a plant callus culture solution and a composition for dimeric stilbene production, which contains a plant callus culture solution as an active ingredient.

IPC Classes  ?

• C12P 17/04 - Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin
• A01H 4/00 - Plant reproduction by tissue culture techniques

Abstract

The present disclosure provides a compound of a chemical structure having the ability of inhibiting or disintegrating an androgen receptor (AR), or a pharmaceutically acceptable salt of the compound. The present disclosure also provides a composition comprising such a compound or a pharmaceutically acceptable salt thereof. The present disclosure provides a pharmaceutical use of a compound according to the present disclosure, a salt thereof, and a composition comprising same for the treatment or prevention of AR-related diseases. The present disclosure also provides a method for treating or preventing AR-related diseases, comprising administering to a subject in need of treatment an effective amount of a compound according to the present disclosure, a salt thereof, or a composition comprising same.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 295/155 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• C07D 211/26 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Abstract

The present disclosure relates to a JAK3 gene-mutated severe combined immunodeficiency animal model and a method of constructing the same. In the JAK3 gene-mutated severe combined immunodeficiency animal model of the present disclosure, the JAK3 gene is specifically deficient, the expression of cytokines is regulated by controlling the number and activity of macrophages, and the thymus, lymphocytes, and Peyer's patches, which are observed in conventional severe combined immunodeficiency animal models, particularly mini-pigs, are completely lacking. In addition, the animal model of the present disclosure can be used as a treatment model for JAK3 SCID patients, as similar phenotypes are observed in patients with human severe combined immunodeficiency caused by a JAK3 gene mutation, and can be used for artificial blood development or xenotransplantation.

IPC Classes  ?

• A01K 67/027 - New or modified breeds of vertebrates
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

The present invention relates to a technology for analyzing and detecting/diagnosing a target nucleic acid. When the detection system according to the present invention is used, effective real-time detection or diagnosis efficiency can be obtained while problems such as noise are minimized. In particular, since, by using a house-keeping gene according to a method of use, the expression difference of the target nucleic acid can be corrected, and direct real-time target nucleic acid detection is possible, it can be effectively used for detecting various nucleic acids and diagnosing various diseases thereby.

IPC Classes  ?

• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The present invention relates to an enzyme for producing hydroxy derivatives of polyunsaturated fatty acids, a method for producing hydroxy derivatives of polyunsaturated fatty acids using the same, and an SPMs complex composition containing the hydroxy derivatives of polyunsaturated fatty acids. The present invention relates to an enzyme for producing hydroxy derivatives of polyunsaturated fatty acids, a method for producing hydroxy derivatives of polyunsaturated fatty acids using the same, and an SPMs complex composition containing the hydroxy derivatives of polyunsaturated fatty acids. The enzyme may produce hydroxy derivatives of polyunsaturated fatty acids in a single reaction, and thus may be very usefully used for in vitro production. In addition, the SPMs complex composition containing the hydroxy derivatives of polyunsaturated fatty acids promotes collagen production, inhibits the production of NO and expression of TNF-α and IL-6, increases the expression of filaggrin and loricrin, and thus may be usefully used for preventing or alleviating skin aging or wrinkles, strengthening skin barrier, or preventing, alleviating or treating skin diseases comprising atopic dermatitis.

IPC Classes  ?

• A61K 8/365 - Hydroxycarboxylic acidsKetocarboxylic acids
• A61Q 19/08 - Anti-ageing preparations
• C12P 7/6432 - Eicosapentaenoic acids [EPA]
• C12P 7/6434 - Docosahexenoic acids [DHA]
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase

Abstract

The present invention relates to a novel cinnamamide derivative and a use thereof in preventing or treating cancer.

IPC Classes  ?

• C07C 235/80 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
• C07D 213/30 - Oxygen atoms
• A61P 35/00 - Antineoplastic agents
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

SYT11SYT11 gene. Also provided in the present invention is a method for providing information necessary for the diagnosis of diffuse type gastric cancer or for determining a therapeutic strategy for diffuse type gastric cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer